Pharmaceuticals

Green Thumb Industries Inc.

Green Thumb Industries Chairman and CEO Benjamin Kovler Sells 2,500 Super Voting Shares at $780 per Share

Green Thumb Industries Inc. released FY2026 Q1 earnings on May 6 After-Market EST, actual revenue USD 300.19 M (forecast USD 297.64 M), actual EPS USD 0.0667

Green Thumb Industries Inc. reports first-quarter financial results

Green Thumb Applies for Federal Registration of Medical Marijuana Business

Green Thumb Industries Inc. to Release FY2026 Q1 Earnings on May 6 After-Market EST, Forecast Revenue USD 297.64 M

Green Thumb Industries Inc. released FY2025 annual earnings on February 25 After-Market (EST), actual revenue USD 1.175 B (forecast USD 1.16 B), actual EPS USD 0.4881

Green Thumb Industries Inc. released FY2025 Q4 earnings on February 25 After-Market EST, actual revenue USD 311.13 M (forecast USD 296.05 M), actual EPS USD 0.3587

Green Thumb Industries Inc. to Release FY2025 Q4 Earnings on February 25 After-Market EST, Forecast Revenue USD 296.05 M

Neal Gilmer Maintains Buy Rating for Green Thumb Industries and Sets Price Target

Green Thumb Industries Inc. released FY2025 Q3 earnings on November 5 After-Market EST, actual revenue USD 291.37 M (forecast USD 290.91 M), actual EPS USD 0.1

Green Thumb Industries Inc. released FY2025 9 Months Earnings on November 5 After-Market EST, with actual revenue of USD 864.17 M and EPS of USD 0.1251

Green Thumb Industries Inc. Reports Q3 2025 Financial Results

Green Thumb Industries Inc. to Release FY2025 Q3 Earnings on November 5 After-Market EST, Forecast Revenue USD 290.91 M

Green Thumb Industries Inc. Announces $50 Million Stock Repurchase Program

Green Thumb Industries Inc. released FY2025 Semi-Annual earnings on August 7 After-Market EST, actual revenue USD 572.8 M, actual EPS USD 0.03

Green Thumb Industries Inc. released FY2025 Q2 earnings on August 6 After-Market EST, actual revenue USD 293.26 M (forecast USD 280.58 M), actual EPS USD -0.0099

Green Thumb Industries Reports Q2 2025 Financials

Green Thumb Industries Inc. to Release FY2025 Q2 Earnings on August 6 After-Market EST, Forecast Revenue USD 280.58 M

Green Thumb Industries Inc. to Release Q2 2025 Earnings

Green Thumb Industries Announces Third Mendocino's Miracle Cannabis Festival

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

GTBIF

Green Thumb Industries (CNSX:GTII) reported Q1 2026 sales of US$300.19 million and net income of US$15.4 million, indicating a recovery in share price with a 1-day return of 2.5% and a 90-day return of 10.81%. The stock is currently undervalued at CA$9.84, compared to a fair value of CA$18.08. The company faces challenges due to federal legal ambiguity affecting institutional investment, but potential policy reforms could enhance its valuation. Analysts suggest a cautious outlook with a P/E ratio of 12.9x, above the estimated fair ratio of 11.2x.

Simplywall

Assessing Green Thumb Industries (CNSX:GTII) Valuation After Strong Q1 2026 Earnings And Share Price Recovery

TCNNF

TLRY

CURLF

CRON

MSOS

A new report from the Global Cannabis Network Collective and Whitney Economics highlights pricing compression as a key indicator of cannabis market maturity. It analyzes how expanding supply and evolving regulations impact pricing across emerging markets in Europe and Latin America. The report emphasizes that while initial market prices may be high, sustained downward pressure is common as markets mature. It also discusses the influence of regulatory frameworks and consumer behavior on pricing stability and operator profitability, providing insights for investors and policymakers.

prnewswire

Trulieve Cannabis Corp.

Tilray Brands

Aurora Cannabis

Curaleaf Holdings, Inc.

Canopy Growth

Cronos

AdvisorShares Pure US Cannabis ETF

Amplify Alternative Harvest ETF

07:05 ETNew Global Cannabis Report from GCNC and Whitney Economics Examines How Pricing Compression Reshapes Emerging Markets

CRLBF

IIPR

VICE

The recent rescheduling of cannabis from Schedule I to Schedule III under the Controlled Substances Act marks a significant regulatory shift for the U.S. cannabis industry. CEOs from major cannabis companies highlight key implications for investors, including improved cash flow, better access to banking services, potential uplisting on exchanges, and increased interest from institutional investors. However, there are concerns about overly optimistic timelines for recreational cannabis rescheduling, as support for such changes remains limited.

CabotWealthNetwork

Cresco Labs Inc.

Innovative Industrial Properties

AdvisorShares Vice - ETF

Here’s What “Rescheduling” Really Means for Investors

Haywood analyst Neal Gilmer has reaffirmed a Buy rating on Green Thumb Industries (GTBIF) with a price target of C$20.50. He focuses on the Healthcare sector and has an average return of 0.6% with a 44.38% success rate on his stock recommendations. Additionally, Alliance Global Partners also maintains a Buy rating on the stock, setting a higher price target of C$25.00.

Tip Ranks

Haywood Remains a Buy on Green Thumb Industries (GTBIF)

CBSTF

IMCC

New cannabis regulations are creating disparities between medical-only operators and multistate companies. Medical operators like True Leaf may benefit from improved margins and cash flow, while multistate firms face new tax challenges that could impact earnings. This federal shift in cannabis tax policy is reshaping the industry landscape, influencing valuations and financial performance for various players.

nasdaq

The Cannabist Company Holdings Inc.

IM Cannabis

NVIDIA

Intel

S&P 500

Nasdaq

NVIDIA Corporation

New Cannabis Rules Just Created Winners and Losers: What the Split Schedule Means for Medical Operators and MSOs

Green Thumb Industries (OTC: GTBIF) is predicted to double in stock value within three years, driven by potential catalysts such as federal marijuana reclassification and access to traditional financial services. The company has a strong balance sheet, positive earnings, and operates in attractive markets. Analysts rate the stock a "buy" with a consensus 12-month price target suggesting over 130% upside. However, concerns about its steep valuation, trading at 41 times forward earnings, temper enthusiasm. Investors are advised to consider other top stocks identified by analysts before investing in Green Thumb.

S&P Global

Netflix

Prediction: Green Thumb Industries Stock Will Double Within 3 Years

Marijuana rescheduling is a significant milestone for the industry, particularly benefiting U.S.-based multi-state operators like Curaleaf and Green Thumb, as it reduces their tax burdens. However, it does not legalize marijuana or guarantee benefits for all pot stocks, especially Canadian companies like Tilray Brands, which remain affected by federal bans. Investors should be cautious, as not all stocks will see gains from this news, and Tilray's stock has already declined significantly this year. The Motley Fool suggests exploring other investment options over Tilray.

Marijuana Rescheduling Has Arrived. Don't Make This Mistake

The U.S. Justice Department, led by Acting Attorney General Todd Blanche, is moving to reclassify certain types of marijuana from Schedule I to Schedule III, reflecting a shift in drug policy. This change aims to enhance medical treatment accessibility and promote scientific research on cannabis. A hearing is scheduled for June 29 to discuss further classification changes. The White House supports this initiative, which seeks to reduce restrictions on clinical research hindered by the previous Schedule I designation. This policy change indicates a growing federal openness to reevaluating cannabis regulations.

rttnews

U.S. Moves To Reschedule Marijuana To Schedule III, Expands Research Pathways

Green Thumb Industries Inc.(GTBIF.US)